
    
      This study is being conducted for the treatment of eligible participants who have taken part
      in Study PRM-151-202 and received the open-label study drug or completed the Phase III Study
      WA42293 with PRM-151. Participants who have discontinued treatment from or have completed
      Study WA42293 and do not want to receive PRM-151 in this study, will be invited to enroll in
      survival follow-up.
    
  